{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.3","upperLimit":"46.0","value":"32.8"},{"groupId":"OG001","lowerLimit":"23.3","upperLimit":"48.0","value":"34.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Objective response rate was defined as the percentage of the participants in the analysis population who had a complete response (CR) or partial response (PR). Complete Response: disappearance of all target lesions. Partial Response: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Responses were based upon blinded central imaging vendor per RECIST 1.1. The point estimate and 95% confidence interval for the ORR, were provided using an exact binomial distribution (Clopper and Pearson method). Participants without response data were counted as nonresponders. The data cutoff date was 09-SEPT-2019.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 35 cycles (up to approximately 2 years).","id":"OG000","title":"Cohort A - Pembrolizumab 200 mg"},{"description":"Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants received pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 35 cycles (up to approximately 2 years).","id":"OG001","title":"Cohort B - Pembrolizumab 200 mg"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 48 months","title":"Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}